Health·2,827 stories
Health News
Today’s brief
When Discovery Outruns Delivery
Breakthroughs are arriving fast—an oral obesity pill, a THC therapy for PTSD, a new multiple myeloma drug—while the systems built to distribute them stall, fracture, or skip the people who need them most. This week's stories expose the widening gap between what science can now do and what regulators, payers, and clinics actually deliver.
Aleniglipron's 12% oral result threatens to break the cold-chain economics of injectable semaglutide, and Cambridge researchers mapped why opposing obesity drugs both work. The Guardian analysis lands the harder truth: GLP-1s only save money for top earners, leaving the NHS to deepen the health inequality the drugs were supposed to fix. The science is converging; delivery is diverging.
The AAP's 67,000 pediatricians are preparing to fight federal vaccine misinformation in court. Trump is splitting the MMR. The FTC is probing Epic Systems over health data dominance. Yet the FDA approved Bristol's Zenbexus for advanced myeloma on the same week. The U.S. federal health apparatus is no longer one thing—it's a split screen of deregulating immunization, policing data monopolies, and still approving cancer drugs.
Rising CO2 is measurably shifting human blood chemistry within decades. Stanford found peripheral blood cells flooding aging brains. Gut microbes cannibalize the intestinal lining when fiber disappears. Each finding says the same thing: environmental and physiological stresses accumulate in ways that standard biomarker panels haven't learned to track yet.
U.K. coroners aren't testing for sodium nitrite in suspected suicides, leaving 164 confirmed deaths almost certainly a fraction of the real toll. No medical training is required to inject penis fillers in Britain, so men land in A&E. NHS access to GLP-1s mirrors income. The pattern is regulatory and clinical blind spots, with preventable harm accumulating where no one is counting.
Face2Gene AI Helps Diagnose Rare Diseases
Patients, families, doctors, and nurses are turning to AI tools like Face2Gene to help identify rare and hard-to-diagnose diseases, reflecting growing adoption of the technology beyond clinical settin
UMCG: Low-Dose Digoxin Cuts Heart-Failure Hospitalizations 25%
Three new studies led by University Medical Center Groningen researchers show that low-dose digoxin, a centuries-old heart drug costing less than ten cents a day, reduces heart-failure hospitalization
A little movement in midlife could pay off for your brain years later
New research from UT Health San Antonio suggests that modifiable cardiovascular health factors in midlife — including exercise and blood sugar control — may meaningfully slow cognitive decline decades
Low-Impact Exercise Protects Aging Joints
Avoiding movement is a common mistake that can worsen aging joint pain, according to a sports medicine researcher who argues that low-impact exercise nourishes cartilage, strengthens protective muscle
Flies migrate globally and pollinate more than we think
A naturalist argues that flies deserve far more credit, detailing how billions migrate globally each spring, how hoverflies and even biting midges pollinate plants — including the source of chocolate
Aging trades walking efficiency for ankle stability
New Australian research finds that as people age, their bodies stiffen the ankle with each step to prioritize balance over efficient movement — explaining slower, more tiring walks and a higher fall r
MP Demands Fossil Export Controls After Dorset Collection Sold to Abu
A Liberal Democrat MP is calling on the UK government to extend export controls to fossils after a landmark Jurassic Coast collection was sold to Abu Dhabi for an eight-figure sum, with neither UK mus
NASA COFFIES AI Spots Solar Storms Hours Early
NASA's COFFIES machine learning system can detect storm-causing active regions and hidden signs of solar eruptions hours before they become visible, by tracking magnetic energy build-up that precedes
COVID-19 awakens dormant viruses — and one is linked to long COVID
A large NIH-funded Nature study led by Boston Children's Hospital researchers found that COVID-19 can reactivate 11 dormant viruses in hospitalized patients, with reactivation of the poorly understood
Penis Filler Demand Grows Despite Botched-Procedure Risks
A BBC investigation finds rising UK demand for hyaluronic acid penis fillers despite botched procedures causing skin death and blackening, prompting the British Association of Urological Surgeons to i
Questions readers ask about health
Answered from SkimNews coverage · updated 2026-08-10
What happened in health this week?
OpenAI rolled out ChatGPT Health to all US adults, allowing users to link medical records and health apps to the chatbot, with the company claiming its models can reason at "better than clinician level", although this claim was tempered by OpenAI's health lead. Additionally, Google is letting Fitbit's AI health coach read users' medical records to deliver more personalized wellness advice, and OpenAI made GPT-5.6 Luna the default model for free ChatGPT users with unlimited text chats.
Any new medical breakthroughs?
There are no recent medical breakthroughs reported in the provided coverage, but Anthropic has launched Claude Science, a standalone AI product designed to autonomously support scientific research, with an initial focus on drug development for rare and neglected diseases. Additionally, OpenAI has rolled out ChatGPT Health, allowing users to link medical records and health apps to the chatbot, although its capabilities and limitations are still being debated.
What's the big public-health story?
The big public-health story is that the architecture of public health is under pressure, with the CDC facing workforce and budget cuts, and a Senate committee holding Fauci in contempt over pandemic testimony. Additionally, England has seen obesity rates double despite 14 failed strategies, and the public is turning to private preventive medicine. The FDA is also narrowing its clinical decision support oversight, pulling back from medical AI at a time when physicians say they want more input on its rollout.
What new research is worth knowing about?
New research in brain health monitoring has led to the development of proactive tools, including Alzheimer's blood tests, genetic panels, and heart-rate-variability tracking on smartwatches. However, experts caution that most of these tools aren't yet ready for routine consumer use, and their clinical value remains unproven. Additionally, a new wave of AI tools is emerging in medicine, but their efficacy depends on the specific tool, setting, and practitioner's skill, making it essential to focus on validated applications rather than general claims about AI in healthcare.
Get the Health newsletter
Curated health stories, every morning. Free.
No spam. Unsubscribe anytime.